Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
15
pubmed:dateCreated
1990-9-4
pubmed:abstractText
We have recently demonstrated that interleukin 2 (IL-2), when administered in high doses for several days beginning on the day of allogeneic bone marrow transplantation (BMT), markedly diminishes graft-versus-host disease (GVHD) mortality in lethally irradiated mice. An optimal anti-GVHD effect was attained by coadministering T-cell-depleted (TCD) syngeneic marrow. We demonstrate here that the full graft-versus-leukemia effect of allogeneic T lymphocytes is obtained even when GVHD is markedly diminished by the coadministration of IL-2 and TCD syngeneic marrow. This methodology represents an approach to the treatment of leukemia in which the beneficial effects of allogeneic T cells can be exploited while their major deleterious effect, GVHD, is avoided. These results may thus have an impact on the clinical use of BMT for the treatment of hematologic malignancies.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-14801344, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-2307931, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-2584703, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-2649174, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-2650417, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-2653460, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-2679456, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-2790325, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-2933464, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3049804, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3050476, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3056552, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3159825, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3258180, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3259603, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3263543, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3265509, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3296349, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3297107, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3495566, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-3886826, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-6162792, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-6334141, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-7015133, http://linkedlifedata.com/resource/pubmed/commentcorrection/2377601-7135466
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:volume
87
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5633-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.
pubmed:affiliation
Transplantation Biology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
pubmed:publicationType
Journal Article